Coexisting inflammatory bowel disease and eosinophilic esophagitis: moving beyond parallel narratives to an integrated framework.
文献摘要
Introduction Eosinophilic esophagitis (EoE) and inflammatory bowel disease (IBD) are chronic immune-mediated gastrointestinal disorders traditionally framed as biologically distinct, yet epidemiologic data increasingly support a bidirectional association. Areas covered This narrative review examines the epidemiology,immunopathogenesis, and clinical implications of coexisting EoE and IBD using a targeted PubMed search through 2025 with reference-list screening. Although EoE is classically driven by type 2 inflammation and IBD by Th1/Th17 pathways, both disorders converge on epithelial barrier injury, innate immune dysregulation, and fibroblast-mediated remodeling. These shared downstream mechanisms may help explain diagnostic overshadowing, treatment resistance, and an increased propensity for fibrostenotic complications in patients with dual disease. Expert opinion Coexisting EoE and IBD may be better viewed less as a chance overlap and more as a potentially meaningful clinical association. A mechanism-based approach that incorporates risk enrichment, early endoscopic evaluation, nutritional comanagement, and therapies directed at shared inflammatory-fibrotic pathways may improve outcomes. Future progress will depend on prospective cohorts, biomarker development, and trials that intentionally include patients with both conditions.